<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>LUPUS.knit</title>

<script src="site_libs/header-attrs-2.28/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/font-awesome-6.4.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet" />
<!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-S761Y2PE6H"></script>
    <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());
    
    gtag('config', 'G-S761Y2PE6H');
    </script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>







<link rel="stylesheet" href="styles.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}

.tocify-subheader {
  display: inline;
}
.tocify-subheader .tocify-item {
  font-size: 0.95em;
}

</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Renal Medicine</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Research
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./trials.html">Active Metro North KHS Trials</a>
    </li>
    <li>
      <a href="./research_output.html">KHS Research Activity Overview</a>
    </li>
    <li>
      <a href="./full_pubslist.html">KHS Publication list</a>
    </li>
    <li>
      <a href="./posters.html">Posters and Abstracts</a>
    </li>
    <li>
      <a href="./nephronexus.html">Nephronexus: Publically available Data</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GEN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HTN.html">HTN</a>
    </li>
    <li>
      <a href="./CCF.html">CCF</a>
    </li>
    <li>
      <a href="./DKD.html">DKD</a>
    </li>
    <li>
      <a href="./Stones.html">Stones</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    U&amp;E
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./acidbase.html">H+ &amp; HCO3</a>
    </li>
    <li>
      <a href="./na.html">Na</a>
    </li>
    <li>
      <a href="./k.html">K</a>
    </li>
    <li>
      <a href="./mg.html">MG</a>
    </li>
    <li>
      <a href="./renalbone.html">Ca2+ &amp; PO4</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./MCD.html">MCD</a>
    </li>
    <li>
      <a href="./ANCA.html">ANCA</a>
    </li>
    <li>
      <a href="./IGAN.html">IGAN</a>
    </li>
    <li>
      <a href="./MPGN_C3G.html">MPGN &amp; C3G</a>
    </li>
    <li>
      <a href="./LUPUS.html">LUPUS</a>
    </li>
    <li>
      <a href="./FSGS.html">FSGS</a>
    </li>
    <li>
      <a href="./TMA.html">TMA</a>
    </li>
    <li>
      <a href="./GBM.html">GBM</a>
    </li>
    <li>
      <a href="./MN.html">MN</a>
    </li>
    <li>
      <a href="./Amyloid.html">Amyloid</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    CKD
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Checklist</a>
    </li>
    <li>
      <a href="./project1.html">Conservative care</a>
    </li>
    <li>
      <a href="./anaemia.html">Anaemia</a>
    </li>
    <li>
      <a href="./project1.html">Pruritis</a>
    </li>
    <li>
      <a href="./renalbone.html">CKD-MBD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    TX
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Cheat sheet</a>
    </li>
    <li>
      <a href="./txnotes.html">Misc Notes</a>
    </li>
    <li>
      <a href="./nonrenaltx.html">Non Kidney Tx</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    RRT
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HD.html">HD</a>
    </li>
    <li>
      <a href="./project1.html">Home HD</a>
    </li>
    <li>
      <a href="./project1.html">HD Access</a>
    </li>
    <li>
      <a href="./project1.html">PD</a>
    </li>
    <li>
      <a href="./project1.html">CVVH</a>
    </li>
    <li>
      <a href="./project1.html">PEX</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    DRUGS
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./anticoagulation.html">Anticoagulation</a>
    </li>
    <li>
      <a href="./PJP.html">PJP</a>
    </li>
    <li>
      <a href="./abx.html">Abx</a>
    </li>
    <li>
      <a href="./project1.html">Flozins</a>
    </li>
    <li>
      <a href="./rituxcyc.html">RITUX &amp; CYC</a>
    </li>
    <li>
      <a href="./Chemotherapy.html">Chemo</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    MISC
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./preg.html">Pregnancy</a>
    </li>
    <li>
      <a href="./Lymphoproliferative.html">Lymphoproliferative</a>
    </li>
    <li>
      <a href="./covid19.html">SARS-Cov-2</a>
    </li>
    <li>
      <a href="./Tumour_Lysis.html">Tumour Lysis Syndrome</a>
    </li>
    <li>
      <a href="./Single Kidney.html">Single Kidney</a>
    </li>
    <li>
      <a href="./IGG4.html">IGG4</a>
    </li>
    <li>
      <a href="./sjogrens.html">Sjogrens and Systemic Sclerosis</a>
    </li>
    <li>
      <a href="./Curios.html">Wierd and excellent papers</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Path
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./biopsy.html">Biopsy</a>
    </li>
    <li>
      <a href="./path.html">PATH</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Resources
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./edu.html">Educational Resources</a>
    </li>
    <li>
      <a href="./patient_resources.html">Patient Resources</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https:eoindosullivan.com">
    <span class="fas fa-home"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">




</div>


<div id="sle" class="section level1">
<h1>SLE</h1>
<ul>
<li>Up to 60% of SLE patients have lupus nephritis</li>
<li>the female-to-male ratio is highest at reproductive age, ranging
between 8:1 and 15:1</li>
<li>Black and Hispanic SLE patients develop LN earlier and have worse
outcomes than white patients with SLE, including death and ESRD</li>
<li>SLICC criteria for diagnosis of SLE = 10 point and positive ANA</li>
<li>Proliferative lupus nephritis = 10 points! Membranous = 8 so one
other thing will get you there</li>
</ul>
<p>Extra Renal Manifestation</p>
<ul>
<li>Malar Rash</li>
<li>Alopecia</li>
<li>Arthralgia</li>
<li>Fatigue</li>
<li>Thrombocytopaenia</li>
<li>Haemolytic anaemia</li>
<li>more rare : Cardiomyopathy, cerebritis</li>
</ul>
<div class="float">
<img src="images/SLE_dx_criteria.png" alt="Diagnostic criteria" />
<div class="figcaption">Diagnostic criteria</div>
</div>
</div>
<div id="lupus-nephritis" class="section level1">
<h1>Lupus Nephritis</h1>
<ul>
<li><p>Haematuria and proteinuria, AKI/Flare - &gt; CKD</p></li>
<li><p>Proteinuria is often low and doesnt always represent disease
activity (KGIDO 21)</p></li>
<li><p>Most patients with SLE who develop LN do so within 5 years of an
SLE diagnosis and, in many cases, LN is the presenting manifestation
resulting in the diagnosis of SLE</p></li>
<li><p>Within 10 years of an initial SLE diagnosis, 5–20% of patients
with LN develop end-stage kidney disease</p></li>
<li><p>Be Suss: Young women with an ANA or proliferative GN</p></li>
<li><p>Almost always have full house staining (although not
100%)</p></li>
<li><p>Remember that LN classification are not diagnostic guidelines
i.e. you can fulfil criteria but not actually LN</p></li>
<li><p>In LN patients with two risk alleles for APOL1 the odds ratio
(OR) for ESRD was 2.72 (95% confidence interval [95% CI], 1.76 to 4.19;
P&lt;6.2×10−6).</p></li>
<li><p>An HLA-DR2 subtype (HLA-DRB181503), characteristic of black
populations, was linked to worsening proteinuria</p></li>
<li><p>Patients with LN also have a higher standardized mortality ratio
(6–6.8 versus 2.4) and die earlier than SLE patients without LN</p></li>
<li><p>10-year survival improves from 46% to 95% if disease remission
can be achieved</p></li>
<li><p>Extra renal manifestations usually become quiestcent after ESRD
onset @ ~6-12 months of RRT.</p></li>
</ul>
<div id="serology" class="section level3">
<h3>Serology</h3>
<ul>
<li><strong>ANA</strong> = very sensitive, non specific</li>
<li><strong>dsDNA &amp; anti-Smith</strong> = less sensitive but more
specific</li>
<li><strong>C3,C4</strong> = Can be useful for dx and tracking flares.
also low in skin manifestations and haemolytic anaemia</li>
<li><strong>Anti-histone</strong> = Suggests drug induced lupus which
very rarely affects kidneys</li>
<li><strong>Anti Ro/La</strong> = Sjogrens, associated with neonatal
heart block</li>
<li><strong>Anti-RNP</strong> = assoc with lupus cerebritis</li>
<li><strong>Anti phopholipid ab</strong> = anti cardiolipin, lupus anti
coagulant or b2 glycoportein 1 = TMA associations</li>
</ul>
<div id="anti-phospholipid-syndrome" class="section level4">
<h4>Anti phospholipid syndrome</h4>
<ul>
<li>repeated VTE / miscarriages &amp; <strong>Strongly</strong> + tests
- weak + is a common false + (infection)</li>
<li>Present in about 30% of SLE patients</li>
<li>aka hughes syndrome and lupus anticoagulant</li>
<li>misnomer 1: lupus anticoagulant + doesnt mean you have lupus - about
50% of APL patients have SLE</li>
<li>misnomer 2: anticoagulant effect is an in vitro phenomon, in vivo
youre pro thrombotic</li>
<li>injury to the kidney microvasculature, also known as APS
nephropathy</li>
<li>Renal artery/vein thrombosis, VTE, stenosis</li>
</ul>
<p>Catastrophic APS</p>
<ul>
<li>Rapid onset thrombosis, multiple organs, high mortality</li>
<li>High dose steroids, total anticoagulation, PEX +- eculizumab -&gt;
ITU</li>
</ul>
</div>
</div>
<div id="pathopysiology" class="section level2">
<h2>Pathopysiology</h2>
<ul>
<li>Auto-Immune deposits in kidney, unclear aeitiology - theories
include:</li>
<li>Apoptotic cells release DNA/nucelosomes -&gt; antibodies form and
create complexes -&gt; inflammatory cytokines</li>
<li>“planted antigen” - anti dsDNA ab reacts with DNA/nucleosome (neg
charged) trapped in GBM (pos charge)</li>
<li>Cross reactivity between kidney antigens and anti dsDNA : a-actinin,
laminin, heparin sulphate</li>
</ul>
<p>Full house – several variables: usage of frozen vs paraffin / scale
of intensity / note the location of the staining - highly variable</p>
<p>One definition – concurrent + IgA,G,M,C4,C1q, at least 1+ in
intensity and granular, along the capillary walls</p>
</div>
<div id="classification" class="section level2">
<h2>Classification</h2>
<p><a
href="https://www.kidney-international.org/article/S0085-2538(17)30859-1/fulltext">Lupus
classification - ISN 2018</a></p>
<p><img src="images/lupus_classification_diagram.jpg" /></p>
<ul>
<li>15-40% can evolve from one form to another and in an non-sequential
manner</li>
<li>I know this is a bit obvious, but full house is called full house
because you have 3 of a kind and a pair.</li>
</ul>
</div>
<div id="disease-activity" class="section level2">
<h2>Disease activity</h2>
<p>Proliferative components result in poorer outcomes. Signs of
proliferative : / activity &amp; chronicity:</p>
<ul>
<li><p>Endocapillary hypercellularity /neutrophil extravasation ( loops
occluded)</p></li>
<li><p>Fibrinoid necrosis and crescent/fibrocellular formation are actie
leasions and obviously bad</p></li>
<li><p>Hyaline thrombi, wire loops ( due to sub endothelial immune
deposits)</p></li>
</ul>
<p>Proposed modified NIH lupus nephritis activity and chronicity scoring
system</p>
<table>
<colgroup>
<col width="24%" />
<col width="68%" />
<col width="7%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Modified NIH activity index</strong></th>
<th><strong>Definition</strong></th>
<th><strong>Score</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Endocapillary hypercellularity</td>
<td>Endocapillary hypercellularity in &lt;25% (1+), 25%–50% (2+), or
&gt;50% (3+) of glomeruli</td>
<td>0–3</td>
</tr>
<tr class="even">
<td>Neutrophils/karyorrhexis</td>
<td>Neutrophils and/or karyorrhexis in &lt;25% (1+), 25%–50% (2+), or
&gt;50% (3+) of glomeruli</td>
<td>0–3</td>
</tr>
<tr class="odd">
<td>Fibrinoid necrosis</td>
<td>Fibrinoid necrosis in &lt;25% (1+), 25%–50% (2+), or &gt;50% (3+) of
glomeruli</td>
<td>(0–3) × 2</td>
</tr>
<tr class="even">
<td>Hyaline deposits</td>
<td>Wire loop lesions and/or hyaline thrombi in &lt;25% (1+), 25%–50%
(2+), or &gt;50% (3+) of glomeruli</td>
<td>0–3</td>
</tr>
<tr class="odd">
<td>Cellular/fibrocellular crescents</td>
<td>Cellular and/or fibrocellular crescents in &lt;25% (1+), 25%–50%
(2+), or &gt;50% (3+) of glomeruli</td>
<td>(0–3) × 2</td>
</tr>
<tr class="even">
<td>Interstitial Inflammation</td>
<td>Interstitial leukocytes in &lt;25% (1+), 25%–50% (2+), or &gt;50%
(3+) in the cortex</td>
<td>0–3</td>
</tr>
<tr class="odd">
<td><strong>Total</strong></td>
<td></td>
<td><strong>0–24</strong></td>
</tr>
<tr class="even">
<td><strong>Modified NIH chronicity index</strong></td>
<td><strong>Definition</strong></td>
<td><strong>Score</strong></td>
</tr>
<tr class="odd">
<td>Total glomerulosclerosis score</td>
<td>Global and/or segmental sclerosis in &lt;25% (1+), 25%–50% (2+), or
&gt;50% (3+) of glomeruli</td>
<td>0–3</td>
</tr>
<tr class="even">
<td>Fibrous crescents</td>
<td>Fibrous crescents in &lt;25% (1+), 25%–50% (2+), or &gt;50% (3+) of
glomeruli</td>
<td>0–3</td>
</tr>
<tr class="odd">
<td>Tubular atrophy</td>
<td>Tubular atrophy in &lt;25% (1+), 25%–50% (2+), or &gt;50% (3+) of
the cortical tubules</td>
<td>0–3</td>
</tr>
<tr class="even">
<td>Interstitial fibrosis</td>
<td>Interstitial fibrosis in &lt;25% (1+), 25%–50% (2+), or &gt;50% (3+)
in the cortex</td>
<td>0–3</td>
</tr>
<tr class="odd">
<td><strong>Total</strong></td>
<td></td>
<td><strong>0–12</strong></td>
</tr>
</tbody>
</table>
<p><strong>NIH, National Institutes of Health.</strong></p>
<div class="float">
<img src="images/lupus%20algo.png" alt="LN classification" />
<div class="figcaption">LN classification</div>
</div>
<p><a href="https://www.youtube.com/watch?v=IFNHzim4RRo">via Tiffany
Caza on Glomcon</a></p>
<div class="float">
<img src="images/lupus_path_sensitivity.jpg"
alt="Path findings for lupus nephritis" />
<div class="figcaption">Path findings for lupus nephritis</div>
</div>
<p>In the recent ISN revision the group decided that the term
‘endocapillary proliferation’ is a misnomer that should be abandoned and
replaced by the term “endocapillary hypercellularity,” because most of
the hypercellularity in glomerular capillaries in lupus nephritis is
caused by influx of inflammatory cells rather than by actual cell
proliferation in situ.</p>
<p>Future revisions to the classification may remove class VI and
suggest an approach to classify tubular and vascular lesions</p>
<p>Unclear value in even distinguishing between class III and IV. Tricky
business.</p>
</div>
<div id="i---minimal-mesangial-ln" class="section level2">
<h2>I - Minimal Mesangial LN</h2>
<ul>
<li>Normal Light microscopy</li>
<li>Only demonstrable on IF</li>
<li>Remember the easiest place for a complex to deposit is the mesangium
as theres no GBM as a barrier, so its the logical first place to find
early disease</li>
</ul>
</div>
<div id="ii---mesangio-proliferative" class="section level2">
<h2>II - Mesangio proliferative</h2>
<ul>
<li>Now there are some LM findings</li>
<li>Four or more nuclei fully surrounded by matrix in the mesangial area
not including the hilar region</li>
<li>Mesangial cells unhappy and reacting - increase in mesangial cells
and matrix</li>
</ul>
</div>
<div id="iii---focal-proliferative" class="section level2">
<h2>III - Focal Proliferative</h2>
<ul>
<li>20-35% of patients</li>
<li>focal global or segmental involvment ( i.e. invidiual gloms, either
partially or wholly)</li>
<li>Proliferative GN - hypercellularity all types of cell, epithelial,
endothelial, mesangial</li>
<li>Fibrinoid Necrosis and intracapillary thrombi</li>
<li>Wire loop lesions possible on LM ( sub endothelial deposits lead to
homogenous thickening of cap walls)</li>
</ul>
</div>
<div id="iv---diffuse-proliferative" class="section level2">
<h2>IV - Diffuse Proliferative</h2>
<ul>
<li>35-60%</li>
<li>ESRD risk may be as high as 44% over 15 years</li>
<li>Also (hypercellularity) aka proliferative</li>
<li>Involvement now hits &gt;50% of the glom</li>
<li>Bad prognosis</li>
<li>Crescents possible (lesion containing extracapillary
hypercellularity and involving&gt;10% the circumferance of bowmans
capsule)</li>
<li>Cellular cresents are &lt;25% fibrin</li>
<li>Wire loop lesions possible</li>
<li>As recently demonstrated in a meta-analysis by Haring et al. the
clinical importance of distinguishing between segmental and global
lesions in class IV as defined by the ISN/RPS classification system has
been questioned.</li>
</ul>
</div>
<div id="v---membranous-ln" class="section level2">
<h2>V - Membranous LN</h2>
<ul>
<li><p>10-15%</p></li>
<li><p>Membranous lupus (V) can occur concurrent with proliferative
disease (III/IV)</p></li>
<li><p>If &gt;50% of cap loops have sub epithelial electron dense
deposits ( i.e. immunoglob complexs)</p></li>
<li><p>If its &lt;50% then its not called as a membranous component by
pathologist</p></li>
</ul>
<div
id="primary-membranous-and-membranous-lupus-can-often-look-very-similar"
class="section level3">
<h3>Primary membranous and membranous lupus can often look very
similar</h3>
<ul>
<li><p>Clues: full house IF ( i.e. 3 immunoglob heavy chains – IgG, IgA,
IgM, C3, C1q,)</p></li>
<li><p>C1q is reasonably specific for auto immune</p></li>
<li><p>Tubular basement membrane (granular) are not present in primary
membranous but present in lupus membranous</p></li>
<li><p>Often diffuse deposits by EM: Sub endo, epi and mesangial and
tubuloreticular inclusions on the sub endothelial surface of GBM
(interferon “footprints” – also seen in other interferon drive diseases
such as covid and HIV)</p></li>
<li><p>IgG subclasses – would reveal reaction of multiple subtypes –
primary is usually just IgG4 (and sometimes also with IgG1)</p></li>
</ul>
</div>
<div id="membranous-antibodies-antigens" class="section level3">
<h3>Membranous Antibodies &amp; Antigens</h3>
<ul>
<li><p>Unlike primary membranous, antigenic target in membranous lupus
are unknown</p></li>
<li><p>3-5% will be PLA2R+</p></li>
</ul>
<div id="ext1ext2" class="section level4">
<h4>EXT1/EXT2</h4>
<ul>
<li><p>EXT1/2 associated with MN – Dragon fruit appearance on EM,
younger (mean age 38) 80% female, associated with autoimmune disease –
80% had lupus in Mayo series ( in contrast to PLA2R which is
0.55%)</p></li>
<li><p>In Memb lupus in mayo – 33% were EXT1/2 +</p></li>
<li><p>EXT+ basically didn’t progress, despite proliferation! Minimal
proteinuria with baseline however</p></li>
<li><p>Good prognosis! If find an EXT1/2 ensure investigated lupus (
?treated - clarify)</p></li>
<li><p>Stain for EXT1 or 2 (both not required) in PLA2r neg and
autoimmune ( arkana suggestion)</p></li>
<li><p>?whats the antibody</p></li>
</ul>
</div>
<div id="ncam1" class="section level4">
<h4>NCAM1</h4>
<ul>
<li><p>NCAM1 associated with Membranous lupus</p></li>
<li><p>Can have concurrent proliferative component ( 25%
overall)</p></li>
<li><p>NCAM1 is up in CSF post seizures and reactive astrocytes – link
to neuropsychiatric lupus? - speculative</p></li>
<li><p>In arkana series (n=20), mean age 34, 40% had neuropsychiatric
symptoms ( 9% in non NCAM1 +)</p></li>
<li><p>? circulating ? on podocytes. Antibody titres unclear
value</p></li>
<li><p>cohort: Normal function, 6.7 g/protein/day</p></li>
<li><p>Frequency: arkana looked at 220 cases of memb lupus = 6.6% +,
MAYO looked at idiopathic MN 1-2%</p></li>
</ul>
</div>
<div id="tgfbr3" class="section level4">
<h4>TGFBR3</h4>
<ul>
<li><p>TGFBR3 associated with membranous lupus</p></li>
<li><p>Arkana cohort ( n=17)</p></li>
<li><p>50% proliferative component</p></li>
<li><p>16/17 Female, 8.4g/proteinuria day , 13/17 lupus</p></li>
<li><p>Expressed on podocytes - ? whats the antibody</p></li>
</ul>
</div>
<div id="cntn1" class="section level4">
<h4>CNTN1</h4>
<ul>
<li><p>CNTN1 associated MN – Chronic inflammatory demyelinating
polyneuropathy. Contactin 1</p></li>
<li><p>IgG4 dominant ( odd )</p></li>
<li><p>1500 patients with CIDP/acute polyneuritis – older males (67,
10:1 m). 11 antibodies – 5 developed MN (?ref - mayo?)</p></li>
</ul>
</div>
</div>
</div>
<div id="vi---advanced-sclerosing-ln" class="section level2">
<h2>VI - Advanced Sclerosing LN</h2>
<ul>
<li>over 90% fibrosis</li>
<li>End stage disease</li>
<li>Rarely seen, may be scrubbed in next revision of ISN
classification</li>
</ul>
</div>
<div id="non-immune-complex-gn" class="section level2">
<h2>Non immune complex GN</h2>
<ul>
<li>Anti Phospholipid ab associated</li>
<li>thrombotic microangiopathy 24% - can be renal limited</li>
<li>Renal artery/vein thrombosis with infarction</li>
<li>HTN</li>
<li>Livedo reticularis</li>
<li>Necrotising ANCA+ GN ( pauci immune GN in SLE patients, pANCA and
MPO+)</li>
<li>TIN - watch for hyper and hyperkalaemia. quite rare, especially in
isolation.</li>
<li>lupus podocytopathy (defined as nephrotic syndrome in SLE that on
kidney biopsy shows diffuse foot process effacement and no
subendothelial or subepithelial immune deposits) 1.3% . Can lie along
the MCD/FSGS spectrum</li>
<li>hydoxycholoroquine induced - rare - proteinuria and CKD, Biopsy
reveals cytoplasmic inclusions within the podocytes, like Fabrys.</li>
</ul>
<div id="tma" class="section level3">
<h3>TMA</h3>
<p>Approach as standard TMA emergency and requires rapid Dx: urgent
ADAMTS13, APL abx, complement studies, decide if TTP - PLASMIC score (
if 5 or more, PEX/ITU right now). KDIGO 21 has a flow chart</p>
<ul>
<li>if low ADAMts13 this is SLE associated, and needs PEX, steroids +
ritux</li>
<li>if normal &amp; APL ab +, this is AP: nephropathy and needs
anticoagulation and PEX</li>
<li>if net APL ab, it may be complement driven, so if no alternative
then consider eculizumab</li>
</ul>
</div>
</div>
</div>
<div id="treatment" class="section level1">
<h1>Treatment</h1>
<p>The new <a
href="https://kdigo.org/wp-content/uploads/2023/03/KDIGO-2023-Lupus-Nephritis-Guideline_Public-Review_9-Mar-2023.pdf">KDIGO
2023</a> is a good read</p>
<div id="notes" class="section level4">
<h4>Notes</h4>
<ul>
<li>It may be time to move away from thinking of induction/maintenance
and acknowledge the continuous nature of the disease (per <a
href="https://www.youtube.com/watch?v=E4oFaqTKnDk&amp;t=938s">Rovin @
Glomcon</a>)</li>
<li>Lupus has underlying and ongoing autoimmune processes that
periodically erupt into clinical flares</li>
<li>Needs long term attenuation long term to prevent flares and CKD</li>
<li>Probably multi targeted B cells,T cells ,DC and cytokine</li>
<li>When flare occurs – needs acute inflammation stopped rapidly to stop
scarring</li>
<li>Intermittent therapy bursts are needed to attenuate
inflammation</li>
<li>Currently best acute therapy is IV pulse corticosteroids be we need
to eliminate these due to toxicities</li>
</ul>
</div>
<div id="rx-based-on-isn-classification" class="section level3">
<h3>Rx Based on ISN classification</h3>
<ul>
<li><p>Class 2 generally do not need specific therapy for their kidney
disease but may need immunosuppressive treatment for extrarenal SLE
manifestations.</p></li>
<li><p>If nephrotic, treat class 1 &amp; 2 as MCD ( check EM for
podocytes) over 90% of patients given glucocorticoid monotherapy
achieved remission within a median time of 4 week, high risk of flares
so CNI/MPAA/AZA as a second agent (KDIGO 21)</p></li>
<li><p>Patients with mainly chronic injury (any class) or end stage
damage (class 6) also do not need immunosuppression for LN, but may
benefit from antiproteinuric, renoprotective measures.</p></li>
<li><p>The proliferative classes (3 and 4) are often treated with potent
immunosuppression - see below.</p></li>
<li><p>membranous LN (class 5) may be managed conservatively
(antiproteinuric therapy) if patients have subnephrotic proteinuria, or
with immunosuppression if patients have nephrotic range
proteinuria.</p></li>
</ul>
<p><a
href="https://cjasn.asnjournals.org/content/12/5/825#sec-6">Excellent
CJASN overview</a></p>
<p><strong>Natural history with standard of care based on complete renal
remission in placebo arms of notable trial</strong></p>
<ul>
<li>LUNAR 28.5% (multi-ethnic)</li>
<li>ELNT aka Eurolupus 40% (Caucasian)</li>
<li>Dutch working Party on SLE 32.5% (Caucasian)</li>
<li>BMS(CTLA4Ig) aka abatacept 15% (multi-ethnic)</li>
</ul>
</div>
<div id="antimalarials" class="section level2">
<h2>Antimalarials</h2>
<p>A good idea for most lupus patients ( 1c KDIGO 21)</p>
<ul>
<li><p>6mg/kg hydroxychloroquine ( ~400mg/day)</p></li>
<li><p>In an acute flare go for 200mg po bd, 200mg po od is ok for
maintanence.</p></li>
<li><p>during the maintenance phase, this should be lowered to 4 to 5
mg/kg/d.</p></li>
<li><p>Reduce dose by 25% if eGFR &lt;30</p></li>
<li><p>Gladel et al - OR 0.38 for developing LN in SLE if on anti
malarial.</p></li>
<li><p>Relesser et al - OR 0.58 for developing LN in SLE if on anti
malarial, Developing ERSD 0.23, complete response 1.61</p></li>
<li><p>Less thrombosis in APLS.</p></li>
<li><p>Better Lipid profile, bone mass</p></li>
<li><p>Eye toxicity – annual dilated eye examination for retinal
disease, and especially after 5 years</p></li>
<li><p>SE: skin rash, increase in skin pigmentation, muscle weakness,
and visual change or loss of vision</p></li>
<li><p>Note can mimic fabrys - multilamellar zebra bodies in
podocytes</p></li>
<li><p>Rarely can cause cardiomyopathy after several years</p></li>
<li><p>measurement of G6PD : levels is preferred in men, especially
those of African,Asian, or Middle Eastern origin, before starting
hydroxychloroquine (KDIGO 21)</p></li>
</ul>
</div>
<div id="additional-care" class="section level2">
<h2>Additional care</h2>
<p><img src="images/lupus_supportive_care.png" /></p>
</div>
<div id="induction" class="section level2">
<h2>Induction</h2>
<p>Severe proliferative (typically III and IV with or without a V
componentent)</p>
<ul>
<li>Steroids and either 1) MMF 2) CYC 3) Belimumab &amp; MMF/low dose
CYC or 4) MMF and Tac (if eGFR &gt;45)</li>
</ul>
<p><strong>Methylpred:</strong> 500-1000mg for 1-3 days, then oral pred
0.5-1mg/kg/day (ideal body weight) max 60mg taper over weeks to a
maintenance dose.</p>
<p>(Aurora-1): 25mg/day by day 3, wean to 2.5mg by week 16</p>
<p>(BLiss-LN): 25mg by week 7, 10mg by week 12</p>
<p>Plus <strong>CYC or MMF</strong></p>
<ul>
<li><strong>MMF 2-3g/day for 6 months</strong></li>
<li><strong>IV CYC 500mg fortnightly for 3 months - 3 g total
(Eurolupus)</strong></li>
<li>IV CYC 0.5-1g/m2 q monthly * 6 (NIH protocol)</li>
<li>PO CYC 1-1.5mg/kg/d, max 150mg/d for 2-4 months</li>
</ul>
<p>Add on:</p>
<ul>
<li>Tac ( low dose -2mg bd - <a
href="https://doi.org/10.1136/lupus-2016-000169">Chinese Data</a>) &amp;
MMF 500mg bd- if preserved function and intolerance of MMF +- diffuse
podocytopathy</li>
<li>limited data on ritux but may have role if non
responsive/adherence</li>
</ul>
<p>Considerations</p>
<ul>
<li>oral adherence required, CYC may be better in some cases</li>
<li>CYC faster</li>
</ul>
<p>Eurolupus</p>
<ul>
<li>Low dose vs NIH regime</li>
<li>Follow up (5 years and 14 years)</li>
<li>Equally well free of Renal flare/ ESRD</li>
</ul>
<p>Criticism:</p>
<ul>
<li>mostly white northern European patients (however trials from SE asia
and abatacept trial had all patients on Eurolupus trial and no different
was observed suggesting this ethnicity isn’t a concern)</li>
<li>MMF ( Dooley NEJM 2011) – suggests that MMF induction may be
inferior to CYC induction – slightly higher treatment failure ( but non
statistically significant)</li>
</ul>
<div id="kdigo-21-practice-points" class="section level3">
<h3>KDIGO 21 Practice points</h3>
<ul>
<li><p>An MPAA-based regimen is the preferred initial therapy of
proliferative LN for patients at high risk of infertility, patients who
have a moderate to high prior cyclophosphamide exposure, and patients of
Asian, Hispanic, or African ancestry</p></li>
<li><p>triple immunosuppressive regimen that includes a CNI (tacrolimus
or cyclosporine) with reduced-dose MPAA and glucocorticoids is reserved
for patients who cannot tolerate standard-dose MPAA or are unfit for or
will not use cyclophosphamide-based regimens</p></li>
<li><p>In patients with baseline eGFR of at least 45 ml/min per 1.73 m2
, voclosporin can be added to MPAA and glucocorticoids as initial
therapy for 1 year</p></li>
<li><p>There is an emerging role for B lymphocyte targeting biologics in
the treatment of LN. Belimumab can be added to standard therapy in the
treatment of active LN. Rituximab may be considered for patients with
persistent disease activity or repeated flares</p></li>
</ul>
</div>
</div>
<div id="maintenance" class="section level2">
<h2>Maintenance</h2>
<p>Pred taper as above - withdraw pred once sustained remission. Keep
maintainece dose &lt;5 if required.</p>
<p>EULAR 2023 - 3 years IS total.</p>
<ul>
<li><p><strong>MMF 1-2g/day (first choice)</strong></p></li>
<li><p>AZA 1-2.5mg/kg/d (pregnancy / intolerant of MMF)</p></li>
<li><p>CSA 2.5mg/kg/d/TAC (trough 4-6) if MMF/AZA not tolerated</p></li>
<li><p>discontinuation of glucocorticoids can be considered after
patients have maintained a complete clinical renal response for ‡12
months</p></li>
<li><p>total duration of initial immunosuppression plus combination
maintenance immunosuppression for proliferative LN should be over 36
months.</p></li>
</ul>
<p>ALMS maintenance trial NEJM 2011</p>
<p>Time to treatment failure | n=227 | MMF vs AZA | European mild-mod
disease</p>
<p>Maintain nephritis ANN Rheum disease 2010</p>
<p>Time to renal flare | n= | MMF vs AZA |</p>
</div>
</div>
<div id="resistant-ln" class="section level1">
<h1>Resistant LN</h1>
<ul>
<li>Several Clinical trials failed to show a benefit with additional
ritux, including <a
href="https://pubmed.ncbi.nlm.nih.gov/22231479/">LUNAR</a> and <a
href="https://pubmed.ncbi.nlm.nih.gov/20039413/">EXPLORER</a>. Both had
high dose steroids - masked ritux effect? Neither trial selected for
treatment resistance.</li>
<li>Despite this, the totality of evidence via <a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072690/#:~:text=Objective,however%2C%20data%20are%20still%20controversial.">meta-analysis</a>
suggest role for ritux</li>
<li>PEX indicated in any suggestion of CAPS</li>
<li>Role for Belimumab pre/post Ritux – both have been advocated in case
reports</li>
<li>IVIG can theoretically bind to targets on B cells to render ritux
less potent, so may be best to minimise overlap</li>
<li>Ensure maxed all other therapies, re-pulse with steroids, unknown
role for Tacrolimus</li>
</ul>
</div>
<div id="follow-up-closely" class="section level1">
<h1>Follow up closely</h1>
<div id="repeat-renal-biopsy" class="section level2">
<h2>Repeat Renal Biopsy</h2>
<ul>
<li>After completing 6–8 months of immunosuppressive therapy, 20%–50% of
complete clinical renal responders still had histologic evidence of
ongoing active inflammation, and 40%–60% of patients with no histologic
evidence of disease activity still had persistent, high-grade
proteinuria</li>
<li>Even after several years of immunosuppressive treatment, histologic
activity was found in about 20% of patients who had been in sustained
clinical remission.</li>
<li>Conversely, 40% of patients in complete histologic remission after
long-term treatment had persistent clinical findings</li>
<li>probably most useful for patients with class 2 or 5 with a Flare as
this could suggest proliferative disease thus intensification of
immunosuppresion</li>
</ul>
<div id="nih-disease-activty-scores-as-prognosis"
class="section level3">
<h3>NIH disease activty scores as prognosis:</h3>
<p>10 years of follow-up, the probability of doubling serum creatinine
was about 56% for patients whose second biopsy had persistent activity
(an activity index &gt;2), compared with 20% for patients who had an
activity index ≤2 (P&lt;0.001). Similarly, 10-year renal survival was
&gt;90% if the chronicity index of the repeat biopsy was &lt;3, but 55%
if the chronicity index was &gt;6 (P=0.10).</p>
</div>
</div>
</div>
<div id="pregnancy" class="section level1">
<h1>Pregnancy</h1>
<ul>
<li><p>SLE often develops or Flares during pregnanacy or first 8 weeks
post partum. Can mimic preeclampsia/HELLP</p></li>
<li><p>Hydroxychloroquine use in pregnancy has been associated with a
decrease in lupus activity and a satisfactory safety profile in both the
mother and the fetus ( KDIGO 21)</p></li>
<li><p>Patients with active LN should be counseled to avoid pregnancy
while the disease is active or when treatment with potentially
teratogenic drugs is ongoing, and for ~6 months after LN becomes
inactive</p></li>
<li><p>hydroxychloroquine should be continued during pregnancy, and
low-dose aspirin should be started before 16 weeks of gestation</p></li>
<li><p>Only glucocorticoids, hydroxychloroquine, azathioprine, and CNIs
are considered safe immunosuppressive treatments during
pregnancy</p></li>
<li><p>Wean the MMF, ACEi and onto above agents</p></li>
<li><p>2 years post flare is highest risk of recurrnce so if can get two
years out this is optimal</p></li>
<li><p>May be role for pre preg biopsy</p></li>
<li><p>check autoantibodies ( Ro, La, APLS)</p></li>
</ul>
<p><a
href="https://pubs.glomcon.org/approach-to-pregnancy-in-lupus-nephritis/">Nice
summary here</a></p>
<div class="float">
<img src="images/LNpreg1.jpg" alt="key image 1" />
<div class="figcaption">key image 1</div>
</div>
<div class="float">
<img src="images/LNpreg2.jpg" alt="key iamge 2" />
<div class="figcaption">key iamge 2</div>
</div>
<div id="emerging-therapies" class="section level2">
<h2>Emerging therapies</h2>
<div class="float">
<img src="images/bcelltarget.png"
alt="How to Target a B-cell, Brad Rovin @ Glomcon" />
<div class="figcaption">How to Target a B-cell, Brad Rovin @
Glomcon</div>
</div>
<div id="bortezomib" class="section level3">
<h3>Bortezomib</h3>
<p><strong>Bortezomib – proteosome inhibitor</strong></p>
<ul>
<li>Auto ab are made by plasma cells/ blasts</li>
<li>As b cell lineage mature, it loses its CD20 molecule thus arnt
targeted by rituximab</li>
<li>PI blocks NK-kb activation – remembering hat NK-kB is a bit of a
master pro inflammatory regulator</li>
<li>Decreased type 1 IFN activity</li>
<li>Decreased Dendritic cells</li>
<li>Peripheral nervous system off target side effects</li>
<li>Not currently being trialed in LN, bother other PI are</li>
</ul>
<p>Tobias el al Ann rheum disease 2015</p>
<ul>
<li>12 refractory LN patients, 8 with class IV LN, pathogenic ( and
vaccine!) ab reduced, drop in SLEDAI ( activity scale)</li>
<li>C3 improved, Proteinuria declined</li>
</ul>
</div>
<div id="obinutuzumab" class="section level3">
<h3>Obinutuzumab</h3>
<p>Humanized type II anti-CD 20 ( ritux is a type 1 anti CD20)</p>
<p>Approved for CLL and follicular lymphoma</p>
<p>Vs ritux it has 100x ab-dependent cytotoxicity, greater cell death,
reduced internalization, less reliance on complement dependent
cytotoxicity</p>
<p>Superior B cell depletion in patients with RA</p>
<p>Nobility trial – phase 2</p>
<ul>
<li>2 years | n=126 | Obinutuzumab &amp; MMF vs placebo &amp; MMF</li>
<li>~ half were dsDNA + , 10% black | CRR 35 vs 23 ( 1 year) and 40 vs
18% at week 76</li>
<li>Complete response rate increases over time</li>
<li>Much earlier and almost complete b cell depletion vs ritux ( in
historical LUNAR data – ritux peaks around week 12 at 87% and has
declined by week 24 to 52%)</li>
<li>SAE 23 s 30%, infection 6 vs 18%, 1 vs 4 death.</li>
</ul>
</div>
<div id="belimumab" class="section level3">
<h3>Belimumab</h3>
<p>Belimumab is approved in USA for non renal lupus</p>
<p>Antibody vs BLys ( survival factor for b cells)</p>
<p>ITN calibrate – phase 2, open label proliferative LN – steroids + cyc
(750) + ritux week 0,2 and placebo or belimumab at week 4 – Didn’t
suggest any additional benefit</p>
<p>Why? Killing b cells increased serum BLys</p>
<p>Reconstitution of b cells in high BLyS environment fosters auto
reactive B cells</p>
<p>Thus anti BLyS treatment may help sustain a response and prevent
reconstitution</p>
<p>TBC – BLISS LN will be out shortly</p>
</div>
<div id="multitargeted-therapy" class="section level3">
<h3>Multitargeted therapy</h3>
<p>Lower dose of steroids &amp; MMF &amp; CNI</p>
<p>Usually Chinese studies</p>
<p>Voclosporin phase 2 multi target trial ( novel calcineurin inhibitor)
– added to 2g/day MMF and rapid taper of steroids - down to 2.5mg by
week 16 – pretty aggressive taper</p>
<p>Outcomes: low dose was more effective – but disproportionate death in
the low dose group</p>
</div>
<div id="misc-comments-on-treatment" class="section level3">
<h3>Misc comments on treatment</h3>
<p>Anti CD20 therapy also affect T cells, Drops T regs</p>
</div>
</div>
</div>
<div id="idiopathic-full-house-gn" class="section level1">
<h1>Idiopathic full house GN</h1>
<p><a href="https://www.youtube.com/watch?v=thv1tCKDOWM">Ingeborg Bajema
@ Leiden</a></p>
<p><em>Aka Non-lupus full house nephritis, Lupus-like nephritis, a frome
fruste of lupus nephritis, renal limited lupus nephritis.</em></p>
<ul>
<li><p>Is this LN? Renal limited LN? How do we recognize it?</p></li>
<li><p>Usually a bx turns up with full house and “consistent” ( could be
anything) pictures in a patient with no clinical suspicion of
SLE</p></li>
<li><p>It could of course be that this is the first finding of
LN/SLE</p></li>
</ul>
<p>Bajema et al (NDT 2017) | N= 149 LN -&gt; 32 non-lupus full house
-&gt;20 idiopathic/12 atypical variants | Poor renal outcomes | Non
developed SLE |</p>
<p>Other case reports of idiopathic full house GN:</p>
<ul>
<li><p>Membranous due to syphilis (BMJ 2021)</p></li>
<li><p>Drug induced (CJASN 2015)</p></li>
<li><p>Infection related (Clin Nephrology 2020)</p></li>
<li><p>Herbal Medication (BMC 2020)</p></li>
<li><p>HIV (Kidney Int 2005) – 13/17 endo cap hypercellularity, memb in
1</p></li>
<li><p>Can occur post tx</p></li>
</ul>
<p>Rarely can proceed SLE by several years, in paediatric patients
usually tbh</p>
<p>Tubulo-reticular inclusions by EM are useful to differentiate and
identify true lupus (TR inclusions no exclusive to LN)</p>
<p>Check for cryoglobs (especially if MPGN) - of course you can get
cryoglobs with LN</p>
<p>?Might be sensible to treat severe looking histology as a severe LN
in the absence of reversible causes/infections - careful with diagnostic
anchoring to avoid accidently immunosuppression if infection is a
cause</p>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = false;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
